Perry, Indiana 46107
317-782-7819 http://clinicaltrials.stfrancishospitals.org/ spears@ssfhs.org
December 2005, the Indiana Oncology Hematology Consultants (IOHC) Research Department joined St. Francis Hospital and Health Centers. St. Francis wanted to expand their research program and IOHC had the infrastructure in place. As a result the St. Francis Cancer Research Foundation was formed. IOHC physicians continue to participate in clinical trials through the Foundation. In early 2006 the administrative office relocated to St. Francis Hospital in Beech Grove, IN, a suburb of Indianapolis. A 10 member physician board of directors was formed to govern the Research Foundation.
St. Francis Hospital is part of the St. Francis Healthcare system with three facilities in the Indianapolis area. The main hospital (320 beds) is located at 1600 Albany St., Beech Grove, In. A secondary location, the Indianapolis campus at 8111 South Emerson Ave (200 beds) is conveniently located off I-65 south. A third site, Mooresville Hospital (80 beds) located at 1201 Hadley Rd. Mooresville, IN., recently underwent a huge expansion and also offers an outpatient cancer center. All sites are active in clinical research, and we diagnose approximately 1400 cancer cases per year. The Indianapolis campus is an expanding new hospital site for St. Francis. Plans are underway to develop this site as a "Cancer Center of Excellence" to service the south side of Indianapolis and several surrounding counties.
The Research Department is participating in strategic planning for the Cancer Center expansion involving Colo-rectal, Lung and Head/Neck multi-disciplinary physician teams. These teams consist of medical oncologists, gastroenterologists, pulmonologists, surgeons of various specialities, oncology gynecologist, radiation oncologists, ENT, radiologists and pathologists. We work closely with each team's Nurse Navigator to identify potential patients for our trials. Additionally, we have expanded our participation with other Medical Oncology practices, Radiation Therapy and Bone Marrow Transplant. We also have plans to open a limited number of trials in outreach clinics served by the IOHC physicians. Our Medical Oncologists have interests in various sub-specialty areas of solid tumor and hematology/ , renal, melanoma, lung, colon, prostate, pancreas, breast, ovarian, head/neck, multiple myeloma, chronic and acute leukemia, lymphoma and MDS. We have participated in gene therapy studies that require additional bio safety review. 80+% of our studies are with investigational drug.
We have participated in clinical trials with numerous pharmaceutical companies, clinical research organizations and bio-tech companies in the US, Canada and abroad. Including Lilly, Roche, Glaxo Smith Kline, Astra Zeneca, Merck, Pfizer, Johnson and Johnson, Abbott, Boehringer Ingelheim, Schering-Plough, Aventis, Genentech, Covance, Sanofi-Aventis, Pharmanet and I3. Cooperative group trials are accessed through Dayton Clinical Research Program (DCOP). Our GOG membership is through the University of North Carolina. Our expansion into the realm of gene therapy occurred in 2007 and required additional bio-safety level II approval and handling procedures.
We currently offer 50+ pharmaceutical and cooperative group, phase I-IV, in patient and out patient clinical trials. Our local IRB submission deadline is every second Wednesday and the IRB meets every fourth Wednesday. Approval documents are typically available within 10-14 working days after the meeting. We utilize a spiral CT and have dedicated radiologists to read. We are experienced in PK/PD collection and processing. A cold centrifuge for in-patients and capabilities to process exotic labs exists in our stem cell lab. A -70 degree freezer is also available. We are experienced with electronic CRF systems. All our electronic records are 21 CFR Part 11 compliant. Office equipment available to monitors includes phones, fax, copier, and four broadband data jacks for laptops. Our coordinators and pharmacists are experienced with blinded study procedures.
We have a profound commitment to our research program and our patients offering cutting edge therapy as additional avenues for treatment through clinical trials.
Laurence H. Bates MD - IOHC St. Francis Medical
Group
Dr Bates, a founding partner, received his MD from the University
of Kansas School Of Medicine in Lawrence, Kansas. He did his
internal medicine residencies at Akron, Ohio and Methodist Hospital
in Indianapolis, IN. He obtained his hematology-oncology fellowship
at the IU Medical Center in Indianapolis and also the National
Institute of Health. He is a member of the American Society of
Hematologists, Indiana Medical Association, Hoosier Oncology Group,
Indiana Medical Oncology Society and serves on the Board of
Directors for the Central Indiana Blood Center and the Sickle Cell
Center. He is also on the advisory board for the Indiana Chapter of
Hemophilia Society. Dr Bates treats hematology patients and has
special interest in these solid tumors, lung, breast, colon and
prostate. Dr. Bates sees patients at various outreach clinics
throughout Indiana.
Anita Conte MD - IOHC St. Francis Medical
Group
Dr. Conte has been affiliated with IOHC since 1998. She received
her MD from the University of Zurich Medical School in Zurich,
Switzerland. She speaks five languages. She did her residency in
Internal Medicine at the University Hospital in Zurich and at
University Hospital SUNY in Stony Brook, NY. She completed her
hematology-oncology fellowship at NYU Medical Center in New York.
Dr. Conte is Board Certified in Internal Medicine, Hematology, and
Medical Oncology. Her special interests include benign hematology,
coagulation disorders, solid tumors and geriatric oncology. She has
served many outreach Oncology clinics throughout Indiana and
participated in clinical trials through IOHC.
Penny Cooper MD - IOHC St. Francis Medical
Group
Dr. Cooper joined IOHC in July 1984. She is Board Certified in
Internal Medicine, Medical Oncology and Hematology. She accrued
seven years of immunology research experience before attending
medical school. Dr. Cooper received her Medical Degree from Rush
Medical College in Chicago, Illinois and her oncology and
hematology fellowships from the IU School of Medicine in
Indianapolis. An enthusiast for medical research, Dr. Cooper serves
on the IRB Board for St. Francis Hospital and is the Medical
Director of the IOHC lab. She is a member of the Indiana State
Medical Association, American Society of Hematology, Clinical
Oncology and Hoosier Oncology Group. She has published in numerous
journals, abstracts and articles. Dr. Cooper has sub-specialized in
breast, and hematology, though she also treats other solid
tumors.
Stephen Eberwine MD - American Health
Network
Dr. Eberwine graduated from the University Of Cincinnati College of
Medicine in 1997, completed his Residency in Internal Medicine at
Indiana University in 2000 and his Fellowship in Hematology,
Medical Oncology at the Medical University of South Carolina in
2003. Dr. Eberwine is Board Certified in Internal Medicine and
Medical Oncology. He is a member of the American College of
Physicians, American Society of Internal Medicine, AMA, American
Society of Hematology, and Clinical Oncology. Dr. Eberwine is
currently practicing with American Health Network at various
Indianapolis locations as well as the Mooresville Cancer Center. He
sees both hematology and solid tumor patients.
Peter Garrett MD - Cancer Care Group St. Francis Medical
Group
Dr. Garrett did his Internship and Residency in Ontario and Toronto
Canada and his Fellowship in Radiation Oncology at the University
of Toronto. He is also Board Certified. Dr. Garrett has been the
Medical Director for Cancer Services at St. Francis Hospitals since
2002 and the Department Head for Radiation Therapy since 2001. He
remains an adjunct Clinical Assistant Professor for the Department
of Radiation Oncology at Indiana University School of Medicine. Dr.
Garrett is a member of the American College of Radiology and held
positions such as Member of the Board of Chancellors and Chairman
of the Board. He is a past President of the Indiana Society of
Radiation Oncology. Throughout his career he has participated in
numerous research projects and published in a vast number of
journals, abstracts and papers.
David Moore MD - GYN Oncology of Indiana St. Francis
Medical Group
Dr. Moore joined St. Francis in 2006. His specialty area is
gynecologic oncology. He is board certified and the newest member
of our research board of directors. Dr. Moore received his MD from
Indiana University as well as his residency in obstetrics and
gynecology. He completed his fellowship in gynecologic oncology at
the University of North Carolina at Chapel Hill in 1988. Since then
Dr. Moore has held several academic and hospital staff
appointments. He has been extremely active in the GOG, Gynecologic
Oncology Group for several years and practices at the South Emerson
location.
Michael T. Slaughter MD, PhD - IOHC - St. Francis
Medical Group
Dr. Slaughter joined IOHC in 1999 after spending his first year of
private practice in Georgia. Dr. Slaughter received his MD from
Meharry Medical College in Nashville, Tennessee. He completed his
internship at Barnes Hospital and his residency at Jewish Hospital,
both located in St. Louis, Missouri. His fellowship was at M.D.
Anderson Cancer Center in Houston, Texas. Dr. Slaughter is Board
Certified in Internal Medicine and Medical Oncology. While in
medical school Dr. Slaughter took a strong interest in immunology
with a focus on sickle cell anemia. He also specializes in the
treatment of lung, prostate cancer and other solid tumors. Dr.
Slaughter is president elect of the Little Red Door and serves on
the board of the African American Medical Society.
Gregory W. Smith MD - IOHC - St. Francis Medical
Group
Dr. Smith joined IOHC as one of the founding partners upon
completing his hematology-oncology fellowship at the Cleveland
Clinic Foundation in 1984. He received his MD from Indiana
University School of Medicine in 1978 and served his internal
residency at Methodist Hospital in Indianapolis. He is Board
Certified in Internal Medicine and Medical Oncology. Dr Smith
treats solid tumors, anemia and general hematology. He has a
special interest in the treatment of brain tumors and head-neck
cancers. He has participated in numerous clinical trials as a
principal and sub-investigator. Dr. Smith sees patients at IOHC's
North Meridian office, South Emerson and various outreach
locations.
Bridget Sanders MD-Kendrick Regional Center for Colon
and Rectal Care
Dr. Sanders joined Kendrick Regional Center for Colon and Rectal
Care in July 2005. Her speciality is colo-rectal surgery. Dr.
Sanders completed her Internship and Residency at Indiana
University and a Fellowship in colon and rectal surgery at
Cleveland Clinic in Weston Florida. She received numerous honors
and awards during her training. Dr. Sanders is Board Certified in
General Surgery as well as Colon and Rectal Surgery. She is a
member of the American College of Surgeons, American Women's
Surgical Association, American Society of Colon and Rectal
Surgeons, Society of American Gastrointestinal Endoscopic Surgeons
and the AMA. Dr. Sanders is very well published in her field.
Randall C. Trowbridge MD - IOHC - St. Francis Medical
Group
Dr Trowbridge joined IOHC in 1991. He practiced medicine at the
Everett Clinic in Washington for the prior fifteen years. He is
Board Certified in Internal Medicine and Medical Oncology. He
received his MD at Baylor College of Medicine in Berkley,
California and served his internship and residency at the Baylor
College Affiliated Hospitals. He served his fellowship in medical
oncology at the University of Minnesota in Minneapolis. Dr
Trowbridge has served on numerous committees at St. Francis;
Medical Director for the Oncology Service Line, Hospice, Vista Care
Hospice, Medical Ethics, and Chairman of the Cancer Care Committee.
Dr. Trowbridge's special interests include GI malignancies (colon,
pancreas, esophageal, stomach), prostate, breast, hospice and
palliative care.
Cathy Spears, RN
Manager St. Francis Cancer Research Foundation
16 years clinical research experience
38 years nursing / management experience
Linda Frazier, RN
Study Coordinator Pharmaceutical Trials (solid tumor)
8 years clinical research experience
26 years nursing experience
M. Jamal
Study Coordinator Pharmaceutical Trials (hematology)
12 years clinical research experience
22 years healthcare field experience
Practicing Medical Oncologist/Radiation
1986-2001 Karachi/Islamabad, Pakistan
Co-author two head/neck papers
Sub investigator for breast study
Donna Cover
Regulatory Specialist
4 years regulatory experience
22 years healthcare field experience
Cara Beeson
Data Manager
3 years data manager experience
10 years medical oncology office experience
Sue Andry, RN
Data Manager
1 year research experience
40 years nursing / management experience
Jayme Harvey, RN, OCN, CCRP
16 years oncology experience
9 years clinical research experience
Kathryn LaPrees CPhT, BS, CCRP
Billing/Contract Manager
4 years research experience
Our practice primarily draws from Marion County and the six surrounding contiguous counties
Hematology
Oncology
Our Physicians see patients on a consultation basis at multiple hospital satellite based sites throughout the state of Indiana. However, if you participate in a clinical trial in most cases you will need to travel to one of our Indianapolis locations for you study visits. Addresses are listed below. All sites have accessibility to public transportation, numerous restaurants and lodging facilities if an overnight stay is required.
Indiana Oncology Hematology Consultants/St. Francis
Medical Group
North office: 9002 No. Meridian St., Indianapolis,
IN 46260
Indiana Oncology Hematology Consultants/St. Francis
Medical Group
South office: 8111 So. Emerson Indianapolis, IN
46237
Mooresville Hospital
1201 Hadley Rd. Mooresville, IN 46158
St Francis Hospital and Health Centers
1600 Albany St. Beech Grove, IN 46107
Administrative Office
1500 No. Albany St., Suite 1001 Beech Grove, IN 46107
Cathy Spears RN
Director St. Francis Clinical Research
St. Francis Hospital and Health Centers
1500 Albany St. Suite 1001
Beech Grove, IN 46107
USA
317-782-7819, Research Office: 317-782-7820
317-782-7828 (fax)
cathy.spears@ssfhs.org
clinicaltrials.stfrancishospitals.org/
- A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
- A Randomized Phase 2 Study of SCH727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
- A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)
- Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)
- Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)
- Lumiliximab With Fludarabine,Cyclophosphamide,and Rituximab(FCR)Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia(CLL) (LUCID)
- Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
- Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients = 60 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
- Randomized, Multi-Center, Open-Label, Study of Docetaxel Versus Docetaxel/PR104 in Non-Small Cell Lung Cancer (NSCLC)
- Safety, Efficacy, Dose-Finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
- SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717)
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
- Study VEG108844, a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
- Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)
- Trial of CPX-351 in Newly Diagnosed Edlerly AML Patients